Just a note of thanks to Craig Douglas who wrote this article. ILI filed this shelf offering before Christmas. He's picking up on it a little late. He talks about "burning through" over 3 million in the last 9 months and only a little over 1 million cash on hand. $70,000,000 in a shelf offering is about the market value of the whole company. He forgot to mention expenses are usually higher when bringing a product on line. He forgot to mention the deal with Amway and who owns almost half of Interleuken. I really feel sorry for the uninformed investor who reads this garbage and sells their stock. I also feel sorry for the Boston Business Journal for an article like this to be published. I would like to suggest that Amway and Interleuken do not want to loose their listing on the AMEX. I would also like to suggest the shelf offering was more of a poison pill than a way to come up with cash. Look at the low cost to ILI of having a world-wide distribution system already in place. Look at the money they have backing them. Look at the risk-reward. I bought more today and averaged UP. At these prices I will continue to average up or down depending on what the stock does. My guess is that the revenues will send this little gem higher within the next two to three quarters. In the mean time, Craig Douglas, go back to business school. And as long as you write this junk, I will continue to accumulate. Good luck to all those owning this company. I will be surprised of your not richly rewarded.